US · IMA · BIOTECHNOLOGY
ImageneBio Inc (IMA) intrinsic value and stock valuation
$3.92as of 2026-11-21 · Mkt cap 64.18M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
ImageneBio Inc DCF and intrinsic value
InvestorsCraft values IMA with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from IMA’s statements →
ImageneBio Inc Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2018–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $800K | $3.5M | $9.16M | $15.6M | $31M |
| Operating income | -$-48.45M | -$-37M | -$-75.42M | -$-70.9M | -$-34.14M |
| Net income | -$-45.35M | -$-36.57M | -$-68.17M | -$-68.77M | -$-34.12M |
| EPSd | -$-9.31M | -$-757.77K | -$-1.63M | -$-1.9M | -$-948.3K |
| Operating cash flow | -$-47.84M | -$-46M | -$-79.74M | -$-74.11M | -$-60.25M |
| Capital expenditure | $0.00 | $0.00 | -$-410K | -$-1.43M | -$-1.76M |
| Free cash flow | -$-47.84M | -$-46M | -$-80.16M | -$-75.54M | -$-62.01M |
| Total assets | $153M | $141.5M | $192.1M | $172.3M | $247.9M |
| Total debt | $9.99M | $7.52M | $10.7M | $5.69M | $6.99M |
| Net debt | -$-24.97M | -$-31.87M | -$-109.16M | -$-54.23M | -$-225.23M |
| Total equity | $133.1M | $125.9M | $169.8M | $147M | $207.9M |
| Cash and short-term investments | $75.8M | $124.4M | $175.5M | $157M | $232.2M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $800K | $3.5M | $9.16M | $15.6M | $31M |
| Cost of revenue | $1.03M | $1.53M | $1.02M | $64.3M | $47.1M |
| Gross profit | -$-230K | $1.97M | $8.14M | -$-48.7M | -$-16.12M |
| Research and development expenses | $28.5M | $32.1M | $59.7M | $64.3M | $47.1M |
| Selling, general and administrative expenses | $20.7M | $8.39M | $24.9M | $22.2M | $18M |
| Other expenses | -$-1.03M | -$-1.53M | -$-1.02M | -$-64.32M | -$-47.11M |
| Operating expenses | $48.2M | $39M | $83.6M | $22.2M | $18M |
| Cost and expenses | $49.3M | $40.5M | $84.6M | $86.5M | $65.1M |
| Interest income | $2.04M | $7.37M | $7.11M | $2.15M | $20K |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $1.03M | $1.53M | $1.02M | $750K | $540K |
| Ebitda | -$-44.67M | -$-35.03M | -$-67.31M | -$-68.01M | -$-33.57M |
| Operating income | -$-48.45M | -$-37M | -$-75.42M | -$-70.9M | -$-34.14M |
| Total other income/expenses, net | $2.75M | $450K | $7.09M | $2.14M | $20K |
| Income before tax | -$-45.7M | -$-36.55M | -$-68.33M | -$-68.77M | -$-34.12M |
| Income tax expense | -$-350K | $10K | -$-160K | $0.00 | $0.00 |
| Net income | -$-45.35M | -$-36.57M | -$-68.17M | -$-68.77M | -$-34.12M |
| Weighted average shares outstanding | $4.87M | $48.3M | $41.7M | $36.2M | $36M |
| Weighted average diluted shares outstanding | $4.87M | $48.3M | $41.7M | $36.2M | $36M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $75.8M | $124.4M | $175.5M | $157M | $232.2M |
| Net receivables | $1.3M | $0.00 | $0.00 | $0.00 | $0.00 |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $140.3M | $127.2M | $178.7M | $160M | $236.5M |
| Property, plant and equipment, net | $790K | $4.23M | $8.02M | $8.46M | $8.98M |
| Goodwill and intangible assets | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Long-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $2.39M |
| Total non-current assets | $12.7M | $14.3M | $13.4M | $12.3M | $11.4M |
| Total assets | $153M | $141.5M | $192.1M | $172.3M | $247.9M |
| Accounts payable | $1.44M | $900K | $2.07M | $2.09M | $2.38M |
| Short-term debt | $2.26M | $3.78M | $3.56M | $1.91M | $1.85M |
| Deferred revenue | $0.00 | $0.00 | $0.00 | $9.16M | $17.1M |
| Total current liabilities | $11.2M | $10.8M | $14.2M | $21.5M | $27.2M |
| Long-term debt | $7.73M | $3.74M | $7.18M | $3.79M | $5.13M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 | $0.00 | $7.68M |
| Total non-current liabilities | $8.6M | $4.8M | $8.13M | $3.79M | $12.8M |
| Capital lease obligations | $2.98M | $7.52M | $10.7M | $5.69M | $6.99M |
| Total liabilities | $19.8M | $15.6M | $22.3M | $25.3M | $40M |
| Common stock | $10K | $50K | $50K | $40K | $40K |
| Retained earnings | -$-230.05M | -$-331.62M | -$-282.38M | -$-214.22M | -$-145.45M |
| Accumulated other comprehensive income (loss) | $90K | $70K | -$-50K | -$-760K | $0.00 |
| Total equity | $133.1M | $125.9M | $169.8M | $147M | $207.9M |
| Total investments | $40.8M | $85M | $55.6M | $97M | $2.39M |
| Total debt | $9.99M | $7.52M | $10.7M | $5.69M | $6.99M |
| Net debt | -$-24.97M | -$-31.87M | -$-109.16M | -$-54.23M | -$-225.23M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-52.4M | -$-49.23M | -$-68.17M | -$-68.77M | -$-34.12M |
| Depreciation and amortization | $330K | $490K | $1.02M | $750K | $540K |
| Stock-based compensation | $15.4M | $5.29M | $0.00 | $7.53M | $5.18M |
| Change in working capital | -$-19.19M | -$-3.98M | -$-21.67M | -$-15.14M | -$-33.03M |
| Accounts receivable | $0.00 | $0.00 | $0.00 | -$-290K | $360K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | -$-2.82M | -$-1.17M | -$-2.87M | $0.00 | $0.00 |
| Net cash provided by operating activities | -$-47.84M | -$-46M | -$-79.74M | -$-74.11M | -$-60.25M |
| Investments in property, plant and equipment | $0.00 | $0.00 | -$-410K | -$-1.43M | -$-1.76M |
| Acquisitions, net | -$-5.21M | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-5.81M | -$-34.9M | $64.1M | -$-99.28M | -$-1.76M |
| Common stock issued | $65.8M | $0.00 | $37.6M | $0.00 | $131.3M |
| Common stock repurchased | $0.00 | $0.00 | -$-660K | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $135.5M | $0.00 | $76M | $1.09M | $131.7M |
| Net change in cash | $82.4M | -$-80.91M | $60M | -$-172.3M | $69.7M |
| Cash at end of period | $94.5M | $40.3M | $119.9M | $60.8M | $233.1M |
| Operating cash flow | -$-47.84M | -$-46M | -$-79.74M | -$-74.11M | -$-60.25M |
| Capital expenditure | $0.00 | $0.00 | -$-410K | -$-1.43M | -$-1.76M |
| Free cash flow | -$-47.84M | -$-46M | -$-80.16M | -$-75.54M | -$-62.01M |
Line items
Line items
Line items
About ImageneBio Inc
ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.
- CEO
- Kristin Yarema
- Employees
- 15
- Beta
- 0.76
Explore
Frequently asked questions
What is the intrinsic value of ImageneBio Inc (IMA)?
ImageneBio Inc (IMA) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is IMA undervalued?
IMA trades at a price of $3.92 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.